Allergy Immunotherapy Advances: HDM Market Analysis - Pagina 65 di 118

Comprehensive Market Analysis and Forecast for Chronic Venous Insufficiency Through 2034

DelveInsight’s “Chronic Venous Insufficiency Market Insights, Epidemiology, and Market Forecast-2034” analysis presents comprehensive understanding of Chronic Venous Insufficiency, encompassing historical and forecasted epidemiological data as well as market dynamics across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom and Japan.

To discover detailed information about the Chronic Venous Insufficiency market perspective, drug adoption, treatment scenario and epidemiological trends, Access here; Chronic Venous Insufficiency Market Forecast

Notable Highlights from the Chronic Venous Insufficiency Market Analysis:

The Chronic Venous Insufficiency market dimensions across the 7MM was valued at USD 2,652 million in 2025 and is anticipated to expand at a CAGR of 9.5%, reaching approximately USD 5,951 million by 2034.
In September 2025, enVVeno Medical Corporation (Nasdaq: NVNO) stated that it intends to submit a supervisory appeal following the not-approvable letter issued by the U.S. FDA’s Center for Devices and Radiological Health (CDRH). The letter, dated August 19, 2025, was issued in response to the company’s Premarket Approval (PMA) application for VenoValve®, a surgical venous valve implant developed to address severe deep chronic venous insufficiency (CVI).
In August 2025, enVVeno Medical Corporation reported that the FDA has issued a not-approvable letter for its Premarket Approval (PMA) application for VenoValve®, a surgically implanted replacement venous valve intended for patients with severe deep chronic venous insufficiency (CVI).
In July 2025, TR Therapeutics shared findings from a Phase 3 randomized, double-blind, parallel-group study assessing the efficacy, tolerability, and safety of TR987® 0.1% Gel compared to the standard of care for treating leg ulcers caused by chronic venous insufficiency.
In October 2024, InterVene, Inc., a clinical-stage medical device company focused on developing interventional treatments for chronic venous insufficiency (CVI), announced the successful completion of its $13 million Series A funding round. The investment was co-led by new investor Treo Ventures and existing investor RiverVest Venture Partners®. As part of the financing, Brad Vale, founding general partner at Treo Ventures, has joined InterVene’s Board of Directors.
In January 2024, VERIGRAFT achieved significant progress in its TECVI-1 first-in-man trial, having treated half of the participants. The trial reached the final regulatory safety milestone in early January and is showing sustained graft functionality 12 months after treatment.
In March 2024, enVVeno Medical revealed positive topline efficacy data from the SAVVE US pivotal trial for the VenoValve, demonstrating notable clinical improvements. This data was presented at the 2024 American Venous Forum (AVF) Annual Meeting.
The US Chronic Venous Insufficiency marketplace was valued at roughly USD 1,200 million in 2023 and is projected to expand throughout the 2025-2034 forecast timeframe.
By 2034, Laser Ablation/Radiofrequency Ablation is expected to generate the highest revenue at approximately USD 1,787.9 million, while TR987 is forecasted to bring in the lowest revenue at approximately USD 20.3 million across the 7MM.
Across the 7MM, there were roughly 17.64 million diagnosed cases of chronic venous insufficiency (CVI) in 2020, and this number is projected to grow at a CAGR of 1.4% through 2034.
In the US, the prevalence was notably higher in women, with approximately 4,900 cases compared to 1,600 in men, and these figures are expected to rise over the 2025-2034 forecast timeframe.
Additionally, the US recorded around 52.1 million diagnosed cases of chronic venous disease (CVD) in 2020, a number anticipated to reach nearly 64.93 million by 2034, increasing at a CAGR of 1.6%. In 2023, women continued to represent the majority of CVI cases in the US.
Principal Chronic Venous Insufficiency Organizations: enVVeno Medical Corporation, Verigraft, MediWound, TissueTech/Amniox Medical, Alfasigma S.p.A, Boehringer Ingelheim, Takeda, Abbott, Servier, Ten Sun Pharma Company, Pfizer, AstraZeneca, JMI Laboratories, and additional entities
Principal Chronic Venous Insufficiency Therapeutic Candidates: VenoValve, P-TEV, EscharEx, TTAX01, Vessel, Antistax®, Coumarin/troxerutin, Venocur Triplex®, Detralex, Esarin Gel, Sirolimus, ticagrelor, Neutrolin, and additional agents
The Chronic Venous Insufficiency epidemiological analysis based on gender demonstrated that Chronic Venous Insufficiency is more prevalent in women than men.
The Chronic Venous Insufficiency marketplace is expected to experience substantial growth due to the disease’s increasing prevalence and awareness during the forecast timeframe. Furthermore, launching various multiple-stage Chronic Venous Insufficiency pipeline products will significantly revolutionize the Chronic Venous Insufficiency market dynamics.

Understanding Chronic Venous Insufficiency

Chronic Venous Insufficiency (CVI) represents a condition where the veins in the legs are unable to efficiently return blood to the heart, causing blood to pool in the veins. This can result in symptoms such as swelling, varicose veins, pain, and skin changes. CVI is frequently caused by weakened or damaged vein valves, which allow blood to flow backward and accumulate. It is commonly associated with factors such as aging, obesity, pregnancy, and prolonged standing or sitting. If left untreated, CVI can lead to complications such as ulcers or blood clots.

Access complimentary sample for the Chronic Venous Insufficiency Market Forecast, Size & Share Analysis Documentation

Chronic Venous Insufficiency Epidemiological Analysis

The epidemiological analysis section provides insights into the historical, current, and forecasted epidemiological trends across the seven major countries (7MM) from 2020 to 2034. It facilitates recognition of the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiological analysis section additionally provides detailed examination of the diagnosed patient pool and future trends.

Chronic Venous Insufficiency Epidemiological Segmentation:

The Chronic Venous Insufficiency market analysis presents epidemiological examination for the investigation period 2020-2034 across the 7MM segmented into:

Total Prevalent Cases of Chronic Venous Insufficiency in the 7MM
Gender-specific Cases of Chronic Venous Insufficiency in the 7MM
Age-specific Cases of Chronic Venous Insufficiency in the 7MM
Treatable Cases of Chronic Venous Insufficiency in the 7MM

Access the analysis to understand which factors are driving Chronic Venous Insufficiency epidemiological trends @ Chronic Venous Insufficiency Epidemiology Forecast

Chronic Venous Insufficiency Drug Adoption and Pipeline Development Initiatives

The drug adoption section emphasizes the uptake rate of potential therapeutic candidates recently introduced in the Chronic Venous Insufficiency marketplace or anticipated to be launched during the investigation period. The evaluation encompasses Chronic Venous Insufficiency market adoption by drugs, patient uptake by therapeutic modalities, and sales of each drug.

Furthermore, the therapeutic evaluation section facilitates understanding of the drugs with the most rapid adoption and the rationales behind the maximal utilization of the drugs. Additionally, it compares the drugs based on market share.

The analysis additionally covers the Chronic Venous Insufficiency Pipeline Development Initiatives. It provides valuable insights about different therapeutic candidates across various stages and the principal organizations engaged in developing targeted therapeutics. It additionally analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapeutic candidates.

Chronic Venous Insufficiency Therapeutic Candidates and Principal Organizations

VenoValve: enVVeno Medical Corporation
P-TEV: Verigraft
EscharEx: MediWound
TTAX01: TissueTech/Amniox Medical
Vessel: Alfasigma S.p.A
Antistax®: Boehringer Ingelheim
Coumarin/troxerutin: Takeda
Venocur Triplex®: Abbott
Detralex: Servier
Esarin Gel: Ten Sun Pharma Company
Sirolimus: Pfizer
ticagrelor: AstraZeneca
Neutrolin: JMI Laboratories

Discover more about therapeutic candidates positioned to capture major Chronic Venous Insufficiency market share @ Chronic Venous Insufficiency Treatment Landscape

Chronic Venous Insufficiency Market Catalysts

Rising Prevalence Due to Aging Population & Sedentary Lifestyles: Increased cases linked to obesity, prolonged sitting/standing, and growing elderly population are expanding the patient base.
Growing Adoption of Minimally Invasive Treatment Options: Rising preference for procedures like endovenous laser therapy, radiofrequency ablation, and sclerotherapy is boosting market growth.
Technological Advancements in Diagnostic and Therapeutic Devices: Improved vascular imaging tools, compression systems, and catheter-based technologies are enhancing clinical outcomes and driving demand.
Increasing Awareness and Early Diagnosis Efforts: More screening programs, public health campaigns, and physician education are accelerating treatment rates.
Rising Healthcare Expenditure and Access to Vascular Care: Better reimbursement frameworks and expanding specialty clinics support overall market expansion.

Chronic Venous Insufficiency Market Obstacles

High Treatment Costs and Limited Reimbursement in Some Regions: Advanced vein procedures and long-term care products can be expensive, restricting patient access in low-income markets.
Shortage of Skilled Vascular Specialists & Uneven Healthcare Infrastructure: Limited access to trained professionals, especially in rural and developing regions, slows adoption of advanced therapies.
Underdiagnosis and Lack of Disease Awareness Among Patients: Many early-stage CVI cases go untreated due to misdiagnosis or perception that symptoms are cosmetic rather than medical.
Risk of Complications and Recurrence After Treatment: Post-procedural complications such as thrombosis, nerve injury, or need for repeat interventions affect patient and physician confidence.
Competition from Low-Cost Conservative Management: Widespread use of compression stockings and lifestyle-based management reduces demand for higher-priced interventional therapies.

Parameters of the Chronic Venous Insufficiency Market Analysis

Investigation Period: 2020-2034
Coverage: 7MM
Principal Chronic Venous Insufficiency Organizations: enVVeno Medical Corporation, Verigraft, MediWound, TissueTech/Amniox Medical, Alfasigma S.p.A, Boehringer Ingelheim, Takeda, Abbott, Servier, Ten Sun Pharma Company, Pfizer, AstraZeneca, JMI Laboratories, and additional entities
Principal Chronic Venous Insufficiency Therapeutic Candidates: VenoValve, P-TEV, EscharEx, TTAX01, Vessel, Antistax®, Coumarin/troxerutin, Venocur Triplex®, Detralex, Esarin Gel, Sirolimus, ticagrelor, Neutrolin, and additional agents
Chronic Venous Insufficiency Therapeutic Evaluation: Chronic Venous Insufficiency current marketed and Chronic Venous Insufficiency emerging therapeutic candidates
Chronic Venous Insufficiency Market Dynamics: Chronic Venous Insufficiency market catalysts and Chronic Venous Insufficiency market obstacles
Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Chronic Venous Insufficiency Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Chronic Venous Insufficiency Market Access and Reimbursement

About DelveInsight

DelveInsight represents a leading Healthcare Business Consultant and Market Research organization focused exclusively on life sciences. It supports Pharma companies by delivering comprehensive end-to-end solutions to enhance their performance.

It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com

Prurigo Nodularis Market Analysis: Epidemiology Insights and Forecast Through 2034

DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034” document delivers comprehensive understanding of Prurigo Nodularis, historical and projected epidemiology alongside Prurigo Nodularis market dynamics in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast

Notable Highlights of the Prurigo Nodularis Market Report:

The Prurigo Nodularis market valuation is anticipated to expand with a significant CAGR during the investigation period (2020-2034)

In March 2025, Incyte (Nasdaq: INCY) reported findings from its pivotal Phase 3 TRuE-PN clinical investigation program, encompassing the TRuE-PN1 and TRuE-PN2 studies, assessing the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult individuals (18 years and older) with prurigo nodularis (PN).

In March 2025, Incyte (Nasdaq: INCY) reported positive topline outcomes from its pivotal Phase 3 STOP-HS investigation assessing the safety and efficacy of povorcitinib (INCB054707), an oral JAK1 inhibitor, in adults (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Povorcitinib, a selective JAK1 inhibitor, is also being investigated in Phase 3 investigations for vitiligo and prurigo nodularis (PN) and in Phase 2 investigations for asthma and chronic spontaneous urticaria (CSU).

In February 2025, Galderma (SWX:GALD) reported that the European Commission has granted approval for Nemluvio in the EU to manage both moderate-to-severe atopic dermatitis and prurigo nodularis. Nemluvio is now authorized for subcutaneous use in individuals aged 12 and older with moderate-to-severe atopic dermatitis requiring systemic therapy, alongside adults with moderate-to-severe prurigo nodularis eligible for systemic treatment.

According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was documented at 3.27 cases per 10,000 individuals.

In 2023, among the 7MM, the United States possessed the largest diagnosed prevalent population of prurigo nodularis.

According to estimates, in Europe, the highest prevalence of age-specific cases of prurigo nodularis was observed in the 40-59 years age group, constituting over 30% of the total cases in 2023.

DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for managing prurigo nodularis, with several other treatments currently undergoing development.

Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, among others

Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, among others

The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis

The Prurigo Nodularis market is anticipated to expand due to the condition’s rising prevalence and awareness during the projection period. Furthermore, introducing various multiple-stage Prurigo Nodularis pipeline candidates will substantially transform the Prurigo Nodularis market landscape.

Prurigo Nodularis Summary

Prurigo nodularis represents a chronic skin disorder characterized by the development of intensely itchy nodules or bumps on the skin. These nodules can vary in size and color and frequently appear on the arms, legs, or trunk. The itching associated with prurigo nodularis can be severe and persistent, leading to scratching and potentially causing further irritation and skin damage. The exact cause of prurigo nodularis is not fully understood, but it is believed to involve a combination of factors including underlying skin conditions, nerve dysfunction, and immune system abnormalities.

Get a Free sample for the Prurigo Nodularis Market Report

https://www.delveinsight.com/report-store/prurigo-nodularis-market

Prurigo Nodularis Epidemiology

The epidemiology segment delivers intelligence into the historical, current, and projected epidemiology patterns in the seven major countries (7MM) from 2020 to 2034. It facilitates recognition of the causes of current and projected patterns by examining numerous studies and perspectives of key opinion leaders. The epidemiology segment additionally delivers comprehensive analysis of the diagnosed patient population and future patterns.

Prurigo Nodularis Epidemiology Classification:

The Prurigo Nodularis market document presents epidemiological analysis for the investigation period 2020–2034 in the 7MM categorized into:

Total Prevalence of Prurigo Nodularis
Prevalent Cases of Prurigo Nodularis by severity
Gender-specific Prevalence of Prurigo Nodularis
Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast

Prurigo Nodularis Drugs Adoption and Pipeline Advancement Activities

The drugs adoption segment concentrates on the uptake rate of potential drugs recently introduced in the Prurigo Nodularis market or anticipated to launch during the investigation period. The analysis encompasses Prurigo Nodularis market adoption by drugs, patient adoption by therapeutics, and revenue of each drug.

Moreover, the therapeutics evaluation segment facilitates understanding the drugs with the most accelerated adoption and the rationale behind the maximal utilization of the drugs. Additionally, it contrasts the drugs based on market proportion.

The document also encompasses the Prurigo Nodularis Pipeline Advancement Activities. It delivers valuable intelligence about different therapeutic candidates in various phases and the principal companies participating in advancing targeted therapeutics. It also examines recent developments including partnerships, acquisitions, mergers, licensing patent particulars, and other intelligence for investigational therapies.

Prurigo Nodularis Therapies and Key Companies

Nalbuphine ER: Trevi Therapeutics
Nemolizumab: Galderma
Vixarelimab(KPL-716): Genentech
Povorcitinib(INCB-54707): Incyte Corporation
Ruxolitinib Cream: Incyte Corporation
INCB054707: Incyte Corporation
serlopitant: Vyne Therapeutics Inc.
CC-10004: Celgene Corporation
Pimecrolimus: Novartis
Abrocitinib: Pfizer
Dupilumab SAR231893: Regeneron Pharma

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market

Prurigo Nodularis Market Advantages

Novel drug formulations are unlocking the new market outlook and the potential to enhance the QoL of individuals suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options.

Vixarelimab’s dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

Prurigo Nodularis Market Prospects

Increasing population provides a lucrative opportunity to enhance awareness and innovation of therapeutics to drive the prurigo nodularis market.

Due to one approved drug in the market, there is a substantial opportunity for organizations advancing innovative investigational therapies.

Coverage of the Prurigo Nodularis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, among others
Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, among others
Prurigo Nodularis Therapeutic Evaluation: Prurigo Nodularis current marketed and Prurigo Nodularis investigational therapies
Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market obstacles
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry tactics
Prurigo Nodularis Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Prurigo Nodularis Market Access and Reimbursement

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment

Prurigo Nodularis Market Report Introduction
Executive Summary for Prurigo Nodularis
SWOT analysis of Prurigo Nodularis
Prurigo Nodularis Patient Share (%) Overview at a Glance
Prurigo Nodularis Market Overview at a Glance
Prurigo Nodularis Disease Background and Overview
Prurigo Nodularis Epidemiology and Patient Population
Country-Specific Patient Population of Prurigo Nodularis
Prurigo Nodularis Current Treatment and Medical Practices
Prurigo Nodularis Unmet Needs
Prurigo Nodularis Emerging Therapies
Prurigo Nodularis Market Outlook
Country-Wise Prurigo Nodularis Market Analysis (2020–2034)
Prurigo Nodularis Market Access and Reimbursement of Therapies
Prurigo Nodularis Market Drivers
Prurigo Nodularis Market Barriers
Prurigo Nodularis Appendix
Prurigo Nodularis Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com

Cataract Pipeline Insight: Emerging Therapies and Non-Surgical Treatment Approaches

The therapeutic environment for Cataract, the leading cause of blindness globally, is experiencing a paradigm shift as researchers and biopharmaceutical organizations explore non-surgical and disease-modifying alternatives to conventional cataract extraction surgery. Advances in molecular biology, oxidative stress modulation, and crystallin protein stabilization have opened new avenues for pharmacological intervention. Organizations including Nacuity Pharmaceuticals, CGeneTech, and Plex Pharmaceuticals are pioneering efforts to advance innovative agents aimed at delaying, halting, or reversing cataract progression.

DelveInsight’s “Cataract – Pipeline Insight, 2025” presents comprehensive analysis of ongoing clinical and preclinical R&D, spotlighting investigational drug candidates, novel mechanisms of action, and innovative delivery systems. From anti-aggregation agents and antioxidants to topical formulations and gene therapy candidates, the pipeline reflects a robust and diversified approach to tackling cataracts beyond surgery.

This document delivers a detailed overview of investigational therapies across development phases, highlighting trends in administration routes, formulation innovations, and geographic trial distribution. It also examines the critical unmet requirements, strategic collaborations, regulatory designations (e.g., orphan drug and fast track), and scientific breakthroughs that are positioned to redefine the cataract treatment environment in upcoming years.

Interested in learning more about the current treatment landscape and the key drivers shaping the cataract pipeline? Click here: https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Essential Findings from the Cataract Pipeline Report

DelveInsight’s cataract pipeline analysis depicts a strong sector with 5+ engaged participants advancing 5+ investigational drugs for cataract management.
The prominent cataract organizations encompass Nacuity Pharmaceuticals, CGeneTech, Melt Pharmaceuticals, Plex Pharmaceuticals, among others are evaluating their lead assets to enhance the cataract treatment environment.
Notable cataract investigational therapies in various stages of development comprise NPI 002, CGT 1507, Research programme: ocular therapeutics, among others.
In March 2025, Bausch + Lomb (NYSE/TSX: BLCO) voluntarily recalled its enVista intraocular lenses following reports of unexplained complications.

Request a sample and discover the recent breakthroughs happening in the cataract pipeline landscape @ https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Cataract Summary

Cataracts manifest when the lens of the eye becomes cloudy, limiting light reaching the retina and impairing vision. They develop slowly over time and may not cause symptoms in the early stages, but without management, they worsen and can lead to blindness. In New Zealand, cataracts represent a leading cause of vision loss in older adults, primarily due to aging, but can also result from medical conditions, eye injuries, genetics, or medications. Cataracts can also be congenital or develop in children due to infections or trauma.

Common symptoms encompass cloudy or blurry vision, light sensitivity, difficulty with night driving, and changes in vision or eye prescriptions. If cataracts are suspected, a referral to an ophthalmologist for further examination is recommended. Cataracts can be classified by location, with nuclear cataracts affecting the center of the lens causing significant vision impairment, while cortical cataracts may cause less noticeable issues. Early-stage cataracts may be managed with glasses and better lighting, but surgery is required when cataracts interfere with daily life. Cataract surgery is typically performed as a day-stay procedure under local anesthesia with mild sedation.

Find out more about cataract medication @ https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Cataract Treatment Analysis: Drug Profile

NPI 002: Nacuity Pharmaceuticals

Nacuity Pharmaceuticals has advanced an intravitreal implant prototype containing NPI-002, a small antioxidant molecule engineered to slow cataract progression, along with a proprietary injector. The organization has completed non-clinical testing, obtained HREC approval, and plans to initiate a Phase 1/2 clinical investigation in Australia for NPI-002 in the fourth quarter of 2021.

CGT 1507: CGeneTech

CGT 1507 represents a small molecule targeting proteolytic enzymes. Presently in the pre-clinical phase, this compound is being advanced for managing cataracts.

Research Programme: Ocular Therapeutics – Plex Pharmaceuticals

Plex Pharmaceuticals is advancing CAP 1160, a small molecule targeting HSP27 heat-shock protein modulators, as part of its ocular therapeutics program. The molecule aims to enhance the chaperone-like activity (CLA) of alpha-crystallin (AC), a key protein in the eye lens, to reverse, slow, or prevent cataract formation. By improving AC’s CLA, Plex aims to protect damaged lens proteins and prevent aggregation, which is critical for maintaining lens transparency and preventing cataract development.

Learn more about the novel and emerging cataract pipeline therapies @ https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Cataract Therapeutics Classification

By Product Type

Mono
Combination
Mono/Combination

By Stage

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

By Route of Administration

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

By Molecule Type

Oligonucleotide
Peptide
Small molecule

Coverage of the Cataract Pipeline Report

Coverage: Global
Key Cataract Companies: Nacuity Pharmaceuticals, CGeneTech, Plex Pharmaceuticals, among others.
Key Cataract Pipeline Therapies: NPI 002, CGT 1507, Research programme: ocular therapeutics, among others.

Dive deep into rich insights for drugs used for cataract treatment; visit @ https://www.delveinsight.com/sample-request/cataract-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Introduction
Executive Summary
Cataract Pipeline: Overview
Analytical Perspective In-depth Commercial Assessment
Cataract Pipeline Therapeutics
Cataract Pipeline: Late-Stage Products (Phase III)
Cataract Pipeline: Mid-Stage Products (Phase II)
Cataract Pipeline: Early Stage Products (Phase I)
Therapeutic Assessment
Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Perspectives and Conclusion
Analyst Views
Appendix

About Us

DelveInsight represents a leading healthcare-focused market research and consulting organization that delivers clients with superior market intelligence and analysis to facilitate informed business decisions. With a team of seasoned industry specialists and a profound understanding of the life sciences and healthcare domains, we provide customized research solutions and insights to clients throughout the globe. Connect with us to obtain high-quality, accurate, and real-time intelligence to remain ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

Psoriasis Market Analysis: Epidemiology Insights and Forecast Through 2034

DelveInsight’s “Psoriasis Market Insights, Epidemiology, and Market Forecast-2034” document delivers comprehensive understanding of Psoriasis, historical and projected epidemiology alongside the Psoriasis therapeutics market dynamics in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Psoriasis Market with DelveInsight’s In-Depth Report @ Psoriasis Market Size

Notable Highlights from the Psoriasis Market Research Report

In March 2025, SFA Therapeutics announced the presentation of two head-to-head preclinical studies of its oral psoriasis treatment candidate, SFA-002, at the American Academy of Dermatology Annual Meeting in Orlando, Florida.

Psoriasis is prevalent worldwide with a global prevalence of 1% to 8%. It begins in childhood in approximately one-third of cases.

In 2023, the total number of diagnosed prevalent cases of psoriasis in the US was estimated to be around 8,000,000.

Among type-specific cases, approximately 68% of the psoriatic individuals suffer from plaque psoriasis followed by inverse psoriasis in the US.

In 2023, approximately 28% of psoriasis individuals in the US were estimated to suffer from genital psoriasis, followed by those with scalp psoriasis.

The most common variant of Psoriasis is Plaque Psoriasis, affecting about 90% of psoriasis individuals, with about 20%–30% of them suffering from a moderate or severe condition.

The investigation by Armstrong et al. (2021) highlighted the prevalence of psoriasis in adults in the US and how prevalence has changed since 2003. According to the findings, the prevalence of psoriasis in adults in the US was 3.0. The investigation also mentioned that in children younger than 18 years, showed a psoriasis prevalence of 0.128%.

The leading Psoriasis Companies including Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., Leo Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy’s Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, and Genentech, among others.

Promising Psoriasis Pipeline Therapies in various stages of development encompass SOTYKTU (deucravacitinib), ZORYVE (roflumilast), VTAMA (tapinarof), Synthetic Hypericin (SGX302), SCD-044, SFA-002, among others.

Stay ahead in the Psoriasis Therapeutics Market with DelveInsight’s Strategic Report @ Psoriasis Market Outlook

Psoriasis Epidemiology Classification in the 7MM

Diagnosed Prevalence of Psoriasis in Adults in the US
Diagnosed Prevalence of Psoriasis by Types in the US
Diagnosed Prevalence of Psoriasis by Location in the US
Diagnosed Prevalence of Psoriasis in Pediatrics in the US
Diagnosed Prevalence of Psoriasis by Severity in the US

Download the report to understand which factors are driving Psoriasis epidemiology trends @ Psoriasis Prevalence

Psoriasis Market Outlook

Psoriasis represents a chronic relapsing disease, which frequently necessitates long-term therapy. Disease severity, comorbidities, and healthcare access determine the therapy choice for psoriasis. Psoriatic individuals are frequently categorized into two groups: mild or moderate-to-severe psoriasis, depending on the clinical severity of the lesions, the percentage of affected body surface area, and individual quality of life. The market is dominated by TNF inhibitors, interleukin inhibitors, and vitamin D analogs. The market is also driven by the increasing adoption of biologic therapies, expanding emphasis on precision medicine, and expanding topical treatment options. The approvals of oral TYK2 inhibitors and nonsteroidal topical agents have further increased the number of psoriasis treatments, making the market more competitive.

Psoriasis Drugs Market Landscape

A range of agents is available for the symptomatic management of psoriasis. Individuals with mild-to-moderate psoriasis usually receive topical treatments that modulate gene transcription, inhibit cell proliferation and promote keratinocyte differentiation. These cases can be managed topically with glucocorticoids, vitamin D analogs, and phototherapy. Major topical agents encompass corticosteroids, retinoids including tazarotene, and calcineurin inhibitors including tacrolimus, vitamin D analogs including calcipotriene or calcitriol, and combinations including calcipotriol plus betamethasone dipropionate.

Get In-Depth Knowledge on Psoriasis Market Trends and Forecasts with DelveInsight @ Psoriasis Treatment Market

Psoriasis Companies

Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., Leo Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy’s Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, and Genentech, among others.

Coverage of the Psoriasis Market Report

Coverage: 7MM
Study Period: 2020-2034
Psoriasis Companies: Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., Leo Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy’s Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, and Genentech, among others.
Psoriasis Pipeline Therapies: SOTYKTU (deucravacitinib), ZORYVE (roflumilast), VTAMA (tapinarof), Synthetic Hypericin (SGX302), SCD-044, SFA-002, among others.
Psoriasis Market Dynamics: Psoriasis Market Drivers and Barriers
Psoriasis Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Psoriasis Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight’s Comprehensive Psoriasis Market Report @ Psoriasis Market Drivers and Barriers

Table of Content

Key Insights
Executive Summary of Psoriasis
Competitive Intelligence Analysis for Psoriasis
Psoriasis: Market Overview at a Glance
Psoriasis: Disease Background and Overview
Patient Journey
Psoriasis Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Psoriasis Unmet Needs
Key Endpoints of Psoriasis Treatment
Psoriasis Marketed Products
Psoriasis Emerging Therapies
Psoriasis: Seven Major Market Analysis
Attribute analysis
7MM: Market Outlook
Access and Reimbursement Overview of Psoriasis
KOL Views
Market Drivers
Market Barriers
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About Us

Contact Us

Kanishk

kkumar@delveinsight.com

Contact Us

Kanishk

kkumar@delveinsight.com

Brain Metastases Pipeline Insights: Emerging Therapies and Clinical Developments

DelveInsight’s “Brain Metastases Pipeline Insights 2025” document delivers extensive intelligence regarding 40+ Brain Metastases entities and 45+ investigational drugs within the Brain Metastases pipeline environment. The analysis encompasses Brain Metastases pipeline drug characterizations, incorporating clinical and nonclinical phase candidates. Brain Metastases pipeline document additionally addresses therapeutics evaluation by formulation type, developmental phase, administration pathway, and molecular classification. It also emphasizes the dormant pipeline candidates within this therapeutic area.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Brain Metastases Pipeline Outlook Report

Essential Findings from the Brain Metastases Pipeline Report

On 21 November 2025, Memorial Sloan Kettering Cancer Center initiated an investigation to determine if Cs-131 brachytherapy is effective in individuals with recurrent brain cancer who are scheduled to undergo brain surgery for removal of their tumor(s). The researchers aim to ascertain whether Cs-131 prevents brain tumors from recurring after surgery. The researchers will contrast Cs-131 brachytherapy (which occurs during brain surgery) with the usual approach of brain surgery without brachytherapy. The researchers will compare both the effectiveness and safety of the two approaches.

DelveInsight’s Brain Metastases pipeline document depicts a vigorous sector with 40+ engaged participants advancing 45+ investigational treatments for Brain Metastases management.

The prominent Brain Metastases Companies including HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation among others.

Notable Brain Metastases Pipeline Therapies including GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib among others.

Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Brain Metastases Clinical Trials Assessment

The Brain Metastases Pipeline Report delivers disease summary, pipeline landscape and therapeutic evaluation of the principal pipeline treatments in this field. The Brain Metastases Pipeline Report additionally underscores the unmet requirements regarding the advancement of Brain Metastases.

Brain Metastases Summary

Brain metastases represent a common complication of cancer and the most prevalent type of brain tumor. Anywhere from 10% to 26% of individuals who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured utilizing conventional therapies, long-term survival and palliation are possible with minimal adverse effects to individuals. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for individuals as survival continues to increase.

Brain Metastases Investigational Drugs Profile

ANG1005: Angiochem

ANG1005 represents an innovative targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 constitutes an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which represents one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells utilizing the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.

Azeliragon: Cantex Pharmaceuticals, Inc.

Azeliragon constitutes an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, encompassing HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.

AZD3759: Alpha Biopharma Ltd.

Zorifertinib (AZD3759) represents a type of reversible new generation EGFR TKI, which possesses a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III investigation in July 2022.

From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Brain Metastases Treatment Drugs

The Brain Metastases Pipeline report delivers insights into

The document delivers detailed intelligence regarding entities that are advancing therapeutics for managing Brain Metastases with aggregate treatments developed by each entity for identical purposes.

It evaluates the different therapeutic candidates organized into early-phase, mid-phase, and late-phase of advancement for Brain Metastases Management.

Brain Metastases Companies participate in targeted therapeutics advancement with corresponding active and inactive (dormant or discontinued) initiatives.

Brain Metastases Drugs under advancement based on the developmental phase, administration pathway, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular classification.

Comprehensive analysis of partnerships (company-company partnerships and company-academia partnerships), licensing arrangements and financing particulars for future progression of the Brain Metastases sector.

Brain Metastases Companies

HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation among others.

Brain metastases pipeline document delivers therapeutic evaluation of pipeline drugs by Administration Pathway. Products have been classified under various ROAs including

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Brain Metastases Products have been classified under various Molecular types including

Oligonucleotide
Peptide
Small molecule

Stay updated with the latest Brain Metastases Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Brain Metastases Market Drivers and Barriers, and Future Perspectives

Coverage of the Brain Metastases Pipeline Report

Coverage: Global
Brain Metastases Companies: HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation among others.
Brain Metastases Pipeline Therapies: GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib among others.
Brain Metastases Therapeutic Evaluation by Product Type: Mono, Combination, Mono/Combination
Brain Metastases Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Brain Metastases Emerging Drugs and Companies

Introduction
Executive Summary
Brain metastases: Overview
Pipeline Therapeutics
Therapeutic Assessment
Brain metastases– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ANG1005: Angiochem
Mid Stage Products (Phase II)
Paxalisib: Kazia Therapeutics
Early Stage Products (Phase I)
MW151: ImmunoChem Therapeutics, LLC
Preclinical and Discovery Stage Products
JBI-2174: Jubilant Therapeutics
Inactive Products
Brain metastases Key Companies
Brain metastases Key Products
Brain metastases- Unmet Needs
Brain metastases- Market Drivers and Barriers
Brain metastases- Future Perspectives and Conclusion
Brain metastases Analyst Views
Brain metastases Key Companies
Appendix

About Us

Contact Us

Kanishk

kkumar@delveinsight.com

Evolution of the Global Campylobacter Infections Market

Campylobacter infections remain a formidable public health concern, affecting countless individuals across the globe each year. As one of the leading bacterial causes of foodborne illness, these infections demand urgent attention from healthcare professionals, researchers, and policymakers alike. The Campylobacter Infections Market has witnessed remarkable growth, reflecting the critical need for advanced diagnostic tools, effective treatments, and comprehensive prevention strategies.

What Drives the Campylobacter Infections Market Growth?

The prevalence of campylobacter infections stems primarily from the widespread consumption of contaminated poultry, unpasteurized milk products, and unsafe water sources. Campylobacter jejuni and Campylobacter coli represent the two dominant species responsible for human illness, triggering symptoms that range from mild gastrointestinal discomfort to severe complications such as Guillain-Barré syndrome and reactive arthritis.

Despite advances in food safety protocols and hygiene standards, infection rates continue to climb globally. This persistent trend reflects several underlying factors: evolving food production practices, changing dietary habits, increased international food trade, and the pathogen’s remarkable adaptability. These dynamics create a pressing need for innovative solutions, positioning the market as a critical focal point for healthcare innovation and investment.

Campylobacter Infections Market Research: Breakthrough Diagnostic Technologies

Modern diagnostic approaches have revolutionized the detection and management of campylobacter infections. Campylobacter Infections Market Research demonstrates how cutting-edge molecular techniques have replaced traditional culture-based methods, dramatically reducing the time required for accurate pathogen identification.

Polymerase chain reaction testing now enables clinicians to confirm infections within hours, facilitating prompt treatment decisions and reducing the risk of complications. Whole-genome sequencing technologies provide unprecedented insights into bacterial strain characteristics, antibiotic resistance profiles, and transmission pathways. These capabilities prove invaluable for outbreak investigations, allowing public health authorities to trace contamination sources and implement targeted control measures swiftly.

The development of point-of-care testing devices represents another significant breakthrough. These compact, user-friendly systems bring laboratory-quality diagnostics directly to clinical settings, emergency departments, and even remote healthcare facilities. By eliminating the need for centralized laboratory processing, these innovations accelerate diagnosis, improve patient care, and expand access to quality testing services across diverse healthcare environments.

The Antibiotic Resistance Challenge

Perhaps no issue looms larger over the campylobacter treatment landscape than antibiotic resistance. Over recent decades, these bacteria have developed increasing resistance to fluoroquinolones and macrolides—the antibiotics traditionally prescribed for severe infections. This resistance pattern severely limits therapeutic options and complicates clinical decision-making, particularly for immunocompromised patients and those with life-threatening presentations.

The resistance crisis has spurred intense research into alternative treatment modalities. Pharmaceutical companies are investigating novel antibiotic compounds designed to circumvent existing resistance mechanisms. Simultaneously, researchers are exploring unconventional approaches such as bacteriophage therapy, which harnesses naturally occurring viruses to selectively destroy harmful bacteria while preserving beneficial gut flora.

Probiotic interventions offer another promising avenue. By strengthening the intestinal microbiome, these beneficial bacterial formulations may reduce infection susceptibility, shorten illness duration, and minimize symptom severity. Although still emerging, this approach aligns with growing recognition of the gut microbiome’s crucial role in health and disease resistance.

Campylobacter Infections Market Insight: Prevention and Vaccine Development

Prevention remains the most effective strategy for reducing the burden of campylobacter infections. Campylobacter Infections Market Insight highlights the multifaceted approach required to address this challenge, encompassing food safety improvements, consumer education, and vaccine development efforts.

Food safety regulations have evolved significantly, with governments worldwide implementing stricter testing requirements for poultry processors, dairy producers, and food service establishments. These regulatory frameworks mandate regular pathogen screening, enhanced sanitation protocols, and transparent reporting systems. Compliance with these standards drives demand for testing services, quality assurance systems, and specialized consulting expertise.

Vaccine development represents perhaps the most transformative opportunity in campylobacter prevention. Several vaccine candidates are progressing through preclinical and clinical development phases, targeting both human populations and poultry flocks. A successful poultry vaccine could dramatically reduce bacterial colonization in birds, cutting human exposure at the source. Human vaccines would provide direct protection, particularly benefiting travelers, military personnel, and individuals with compromised immune systems who face elevated infection risks.

Educational campaigns play an essential supporting role by promoting safe food handling practices among consumers and food service workers. Simple measures such as thorough cooking, preventing cross-contamination, and practicing proper hand hygiene can significantly reduce infection transmission, complementing technological and medical interventions.

Campylobacter Infections Market Trends: Digital Health and AI Integration

The intersection of infectious disease management and digital technology is reshaping how healthcare systems detect, track, and respond to campylobacter infections. Campylobacter Infections Market Trends reveal how artificial intelligence and machine learning applications are enhancing surveillance capabilities and predictive accuracy.

Advanced algorithms analyze diverse data streams—including clinical laboratory results, agricultural production data, weather patterns, and food distribution networks—to identify outbreak risks before they materialize. This predictive capacity enables proactive interventions, resource pre-positioning, and early warning systems that protect vulnerable populations more effectively than reactive approaches.

Telemedicine platforms are expanding access to specialized infectious disease expertise, particularly valuable in rural and underserved communities. Patients experiencing symptoms can connect with healthcare providers remotely, receive guidance on symptom management, and determine when in-person evaluation becomes necessary. This accessibility improves outcomes while reducing unnecessary emergency department visits and healthcare costs.

Blockchain technology applications in food supply chain management are gaining momentum. These systems create tamper-proof records documenting each step in food production and distribution, from farm to consumer. When contamination occurs, investigators can rapidly trace products back through distribution channels, identifying contamination points and facilitating targeted recalls that minimize public exposure.

Regional Considerations and Global Perspectives

The campylobacter infections market exhibits substantial regional variation reflecting economic development levels, healthcare infrastructure maturity, and regulatory sophistication. Developed nations benefit from comprehensive surveillance systems, advanced diagnostic capabilities, and robust regulatory enforcement, creating environments conducive to innovation and high-quality care delivery.

Developing regions face different challenges, including limited laboratory infrastructure, healthcare workforce shortages, and resource constraints that impede comprehensive disease monitoring and control. However, these regions also present significant opportunities for companies developing affordable diagnostic solutions, simplified treatment protocols, and prevention programs adapted to local contexts and capabilities.

Future Directions and Emerging Opportunities

The campylobacter infections market stands at a pivotal moment. Converging trends in antibiotic resistance, diagnostic innovation, vaccine development, and digital health integration are creating unprecedented opportunities for stakeholders committed to addressing this persistent public health challenge.

Success will require sustained collaboration among researchers, healthcare providers, pharmaceutical companies, regulatory agencies, and public health organizations. By pooling expertise, sharing resources, and maintaining focus on evidence-based solutions, the healthcare community can make meaningful progress toward reducing infection rates, improving treatment outcomes, and ultimately lessening the global burden of campylobacter-related illness.

Conclusion

The campylobacter infections market represents more than a commercial opportunity—it embodies a collective commitment to protecting public health through innovation, collaboration, and perseverance. As diagnostic technologies advance, treatment options expand, and prevention strategies mature, there is genuine reason for optimism. The path forward demands continued investment, rigorous research, and unwavering dedication to translating scientific discoveries into practical solutions that benefit communities worldwide. Through these efforts, the vision of substantially reducing campylobacter infections transforms from aspiration to achievable reality.

Latest Reports Offered By Delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Kanishk

kkumar@delveinsight.com

Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast 2034

DelveInsight’s “Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2034” analysis presents comprehensive understanding of Intratumoral Cancer Therapies, encompassing historical and forecasted epidemiological data as well as market dynamics across the United States, EU4 nations (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To discover detailed information about the Intratumoral Cancer Therapies market perspective, drug adoption, treatment scenario and epidemiological trends, Access here; Intratumoral Cancer Therapies Market Forecast

Notable Highlights from the Intratumoral Cancer Therapies Market Analysis:

The Intratumoral Cancer Therapies market dimensions are anticipated to expand with a significant CAGR throughout the investigation period (2020-2034)
In January 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology organization dedicated to discovering and developing proprietary immune-based intratumoral cancer therapies, has provided a business update showcasing substantial progress with its lead drug candidate, INT230-6.
In March 2024, ImmVira announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its oncolytic virus product MVR-T3011 IT (intratumoral injection) for treating recurrent or metastatic head and neck squamous cell cancer that has progressed after platinum-based chemotherapy and at least one prior line of anti-PD1/PDL1 therapy.
Several intratumoral therapy strategies, such as immune-enhancing cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, oncolytic viruses (OVs), and plasmid DNA, are currently undergoing clinical development for melanoma patients.
At present, IMLYGIC represents the only intratumoral therapy authorized by the US FDA for melanoma treatment, capturing over 90% of the total market for intratumoral therapies.
Among the emerging therapeutic candidates, OncoSec Medical’s TAVO (tavokinogene telseplasmid), a plasmid-based interleukin-12, is anticipated to generate the highest revenue.
The United States holds approximately 80% of the market share for Intratumoral Cancer Therapies.
An individual’s probability of surviving five years after being diagnosed with cutaneous melanoma improves with earlier diagnosis. Skin melanoma is diagnosed in 81.6% of cases at the local stage, 9% at the regional stage, and 4% at the distant stage when the cancer has spread. Skin-related localized melanoma demonstrated a 5-year relative survival rate of 99.5%
During the prediction timeframe (2021-2022), the United States reported 98,046 instances of melanoma; this number is expected to rise through 2032. In 2021, there were 31,636 cases of melanoma and 91,650 cases of non-melanoma skin cancer (NMSC) in Germany
Nonmelanoma skin cancer (NMSC), one of the nine primary indications for intratumoral treatments, represented the majority of cases across the 7MM. In 2021, there were 793,007 NMSC instances across the 7MM as a whole
Principal Intratumoral Cancer Therapies Organizations: Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and additional entities
Principal Intratumoral Cancer Therapies Therapeutic Candidates: IMLYGIC (talimogene laherparepvec), DELYTACT (G47Δ), AIV001, LTX-315, Vidutolimod + nivolumab, Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and additional compounds
The Intratumoral Cancer Therapies marketplace is expected to experience substantial growth due to the disease’s increasing prevalence and awareness during the forecast timeframe. Furthermore, launching various multiple-stage Intratumoral Cancer Therapies pipeline products will significantly revolutionize the Intratumoral Cancer Therapies market dynamics.

Understanding Intratumoral Cancer Therapies

Any treatment that is administered in very close anatomical proximity to a tumor with the objective of direct uptake by tumors or tumor cells is referred to as intratumoral therapy.

The objective of this therapeutic approach is to have the tumor act as its own vaccination. IT immunotherapies aim to initiate local immune cell recruitment into the tumor microenvironment and then prime T cells for a systemic polyclonal antitumor response (abscopal effect), potentially addressing intra and inter-tumoral heterogeneity. Tumors are utilized as a source of antigens expressed across multiple tumor clones.

Access complimentary sample for the Intratumoral Cancer Therapies Market Analysis – https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Intratumoral Cancer Therapies Epidemiological Analysis

Intratumoral Cancer Therapies Epidemiological Segmentation:

The Intratumoral Cancer Therapies market analysis presents epidemiological examination for the investigation period 2020-2034 across the 7MM segmented into:

Total Prevalence of Intratumoral Cancer Therapies
Prevalent Cases of Intratumoral Cancer Therapies by severity
Gender-specific Prevalence of Intratumoral Cancer Therapies
Diagnosed Cases of Episodic and Chronic Intratumoral Cancer Therapies

Access the analysis to understand which factors are driving Intratumoral Cancer Therapies epidemiological trends @ Intratumoral Cancer Therapies Epidemiology Forecast

Intratumoral Cancer Therapies Drug Adoption and Pipeline Development Initiatives

The drug adoption section emphasizes the uptake rate of potential therapeutic candidates recently introduced in the Intratumoral Cancer Therapies marketplace or anticipated to be launched during the investigation period. The evaluation encompasses Intratumoral Cancer Therapies market adoption by drugs, patient uptake by therapeutic modalities, and sales of each drug.

The analysis additionally covers the Intratumoral Cancer Therapies Pipeline Development Initiatives. It provides valuable insights about different therapeutic candidates across various stages and the principal organizations engaged in developing targeted therapeutics. It additionally analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapeutic candidates.

Intratumoral Cancer Therapies Therapeutic Candidates and Principal Organizations

IMLYGIC (talimogene laherparepvec): Amgen
DELYTACT (G47Δ): Daiichi Sankyo
AIV001: AiViva BioPharma
LTX-315: Lytix Biopharma
Vidutolimod + nivolumab: Regeneron Pharmaceuticals
Vidutolimod (CMP-001): Checkmate Pharmaceuticals
Tavo (tavokinogene telseplasmid): OncoSec Medical Incorporated
CAVATAK (V937; CVA21): Merck
PVSRIPO (PVS-RIPO): Istari Oncology
RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
Daromun (Nidlegy): Philogen
Cotsiranib (STP705): Sirnaomics
Cavrotolimod (AST-008): Exicure
INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
NanoPac (LSAM paclitaxel): NanOlogy
Hensify (NBTXR3/ PEP503): Nanobiotix
AlloStim: Immunovative Therapies
Tasadenoturev (DNX-2401): DNAtrix
Tilsotolimod (IMO-2125): Idera Pharmaceuticals
Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
G207: Treovir
Intuvax (Ilixadencel): Immunicum

Discover more about therapeutic candidates positioned to capture major Intratumoral Cancer Therapies market share @ Intratumoral Cancer Therapies Treatment Market

Parameters of the Intratumoral Cancer Therapies Market Analysis

Investigation Period: 2020-2034
Coverage: 7MM
Principal Intratumoral Cancer Therapies Organizations: Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and additional entities
Principal Intratumoral Cancer Therapies Therapeutic Candidates: IMLYGIC (talimogene laherparepvec), DELYTACT (G47Δ), AIV001, LTX-315, Vidutolimod + nivolumab, Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and additional compounds
Intratumoral Cancer Therapies Therapeutic Evaluation: Intratumoral Cancer Therapies current marketed and Intratumoral Cancer Therapies emerging therapeutic candidates
Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies market catalysts and Intratumoral Cancer Therapies market obstacles
Competitive Intelligence Evaluation: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Intratumoral Cancer Therapies Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Intratumoral Cancer Therapies Market Access and Reimbursement

About DelveInsight

It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com

Comprehensive Pipeline Analysis for Biliary Tumor Therapies 2025

The treatment landscape for biliary tumors, including cholangiocarcinoma and gallbladder cancer, is experiencing substantial innovation, propelled by an expanding pipeline of targeted therapies and immuno-oncology agents. Leading pharmaceutical and biotech organizations such as Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, and Jiangsu HengRui Medicine are actively advancing novel candidates aimed at molecular alterations like FGFR2 fusions, IDH1 mutations, and HER2 amplifications—key drivers of biliary tract malignancies.

DelveInsight’s “Biliary Tumor – Pipeline Insight, 2025” presents a detailed overview of the current clinical development landscape, highlighting investigational drugs across various phases—from early-stage preclinical assets to late-stage pivotal trials. These emerging therapies aim to improve survival and quality of life in patients with limited treatment options and poor prognoses.

This pipeline evaluation delivers a comprehensive view of developmental trends by drug class, mechanisms of action, routes of administration, and trial stages. It additionally explores unmet clinical needs, key regulatory designations, strategic collaborations, and disruptive innovations expected to shape the future of biliary tumor management.

Interested in learning more about the current treatment landscape and the key factors shaping the biliary tumor pipeline? Access here: https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Primary Findings from the Biliary Tumor Pipeline Analysis

DelveInsight’s biliary tumor pipeline evaluation demonstrates a robust space with 50+ active organizations working to develop 55+ pipeline drugs for biliary tumor treatment.
Prominent biliary tumor organizations include Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and additional entities evaluating their lead assets to improve the biliary tumor treatment landscape.
Principal biliary tumor pipeline therapeutic candidates across various developmental stages include Zanidatamab, TT-00420, TQB2102, SHR-A1811, RC48-ADC, MRG003, MDX2001, INT230-6, GQ1001, ELI-002 2P, BL-M07D1, TPX 4589, and additional compounds.
In December 2024, Jazz Pharmaceuticals revealed that the FDA granted accelerated approval for Ziihera® (zanidatamab-hrii) 50mg/mL for intravenous use. It is approved for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC), as detected by an FDA-approved test.
In November 2024, the FDA approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) test to include biliary tract cancer (BTC).
In November 2024, Jazz Pharmaceuticals announced the FDA’s accelerated approval of ZIIHERA® (zanidatamab-hrii) 50mg/mL for intravenous use, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC), as detected by an FDA-approved test.

Request sample documentation and discover the recent breakthroughs occurring in the biliary tumor pipeline landscape @ https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Understanding Biliary Tumors

Biliary tumors, which encompass both benign and malignant growths, arise in the biliary system, comprising the bile ducts and gallbladder. These tumors can obstruct bile flow, resulting in symptoms such as jaundice, pruritus, and potentially serious complications. Malignant biliary tumors, including cholangiocarcinoma and gallbladder cancer, are frequently diagnosed at advanced stages due to their subtle and non-specific early symptoms, resulting in poor prognosis. Key risk factors include chronic biliary inflammation, primary sclerosing cholangitis, liver fluke infections, and genetic conditions. Diagnosis generally involves imaging techniques, endoscopic procedures, and biopsies, while treatment options range from surgical resection to palliative care, depending on the tumor’s classification and stage.

The most prevalent type is extrahepatic cholangiocarcinoma, which is often the most treatable. Hilar cholangiocarcinomas, or Klatskin tumors, occur at the junction of the right and left hepatic ducts and tend to be large and invasive by the time of diagnosis. Symptoms vary depending on tumor location and stage. Patients with extrahepatic cholangiocarcinoma may present with painless jaundice, dark urine, and light-colored stools due to bile flow obstruction, along with abdominal discomfort, weight loss, and fatigue. Hilar cholangiocarcinomas may cause similar symptoms, with jaundice accompanied by pruritus. Intrahepatic cholangiocarcinomas often remain asymptomatic until they grow large enough to cause pain or complications. Some patients may experience pyrexia, nausea, or vomiting.

Discover more about biliary tumor therapeutic interventions @ https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Biliary Tumor Treatment Evaluation: Drug Profiles

Rilvegostomig: AstraZeneca

Rilvegostomig (formerly AZD2936) represents a bispecific antibody developed by AstraZeneca, designed to target both PD-1 and TIGIT to enhance immune responses against cancer. Derived from Compugen’s COM902 antibody, it aims to block these pathways simultaneously, potentially improving therapeutic efficacy. Currently preparing for Phase III trials, rilvegostomig is being evaluated for indications including biliary cancer, non-small cell lung cancer, and gastric cancer. It is additionally being investigated in combination with AstraZeneca’s antibody-drug conjugates like ENHERTU, Dato-DXd, and AZD0901, to maximize its therapeutic potential using its unique bispecific design.

SHR-A1811: Jiangsu HengRui Medicine

SHR-A1811 represents an antibody-drug conjugate (ADC) consisting of trastuzumab, a cleavable linker, and a novel topoisomerase I inhibitor payload, SHR169265. Targeting HER2-expressing tumor cells, it delivers the cytotoxic payload upon internalization. Inside the cell, the linker is cleaved, releasing SHR169265, which inhibits topoisomerase I, an enzyme vital for DNA replication and transcription, leading to cell cycle arrest and apoptosis. SHR-A1811 has demonstrated promising antitumor effects in preclinical studies and is currently being tested in multiple Phase I-III clinical trials for HER2-positive and HER2-low breast cancer, gastric cancer, and other solid tumors. The drug is in Phase II trials for the treatment of biliary cancer.

Discover more about the novel and emerging biliary tumor pipeline therapeutic candidates @ https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Biliary Tumor Therapeutics Evaluation

By Product Classification

Single-agent
Combination
Single-agent/Combination

By Developmental Stage

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

By Administration Route

Oral
Intravenous
Subcutaneous
Parenteral
Topical

By Molecular Classification

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Parameters of the Biliary Tumor Pipeline Analysis

Coverage: Global
Principal Biliary Tumor Organizations: Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceutical, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited, and additional entities.
Principal Biliary Tumor Pipeline Therapeutic Candidates: Zanidatamab, TT-00420, TQB2102, SHR-A1811, RC48-ADC, MRG003, MDX2001, INT230-6, GQ1001, ELI-002 2P, BL-M07D1, TPX 4589, and additional compounds.

Access comprehensive insights for drugs utilized for biliary tumor treatment; visit @ https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Content Organization

Introduction
Executive Summary
Biliary Tumor Pipeline: Overview
Analytical Perspective In-depth Commercial Assessment
Biliary Tumor Pipeline Therapeutics
Biliary Tumor Pipeline: Late-Stage Products (Phase III)
Biliary Tumor Pipeline: Mid-Stage Products (Phase II)
Biliary Tumor Pipeline: Early Stage Products (Phase I)
Therapeutic Assessment
Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Perspectives and Conclusion
Analyst Views
Appendix

About DelveInsight

It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com

Cushing’s Disease Market Analysis: Current Treatment Landscape and Forecast Through 2034

DelveInsight’s Cushing’s Disease Market Insights document encompasses comprehensive understanding of current treatment practices, Cushing’s disease investigational drugs, market proportion of individual therapies, and current and projected market valuation from 2020 to 2034, categorized into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Notable Highlights from the Cushing’s Disease Market Report

According to DelveInsight’s analysis, the market valuation for Cushing’s disease was determined to be USD 1 billion in the 7MM in 2024.

In 2024, among all current therapies for Cushing’s disease, the highest revenue was produced by Mifepristone (KORLYM and generics) in the US.

Based on DelveInsight’s evaluation in 2024, the 7MM possessed approximately 37K diagnosed prevalent cases of Cushing’s disease. These cases are anticipated to increase due to advancements in diagnostic capabilities and heightened awareness about the condition during the projection period (2025–2034).

Leading Cushing’s disease organizations advancing investigational therapies, including Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, among others, are developing innovative Cushing’s disease drugs that can become available in the Cushing’s disease market in upcoming years.

The promising Cushing’s disease therapies in the pipeline encompass DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, among others.

In March 2025, Corcept Therapeutics reported that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to manage patients with endogenous hypercortisolism.

In February 2025, Crinetics Pharmaceuticals mentioned that the organization anticipates initiating enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing’s disease in late 2025 or early 2026.

Discover which therapies are expected to grab the major Cushing’s disease market share @ Cushing’s Disease Market Report

Cushing’s Disease Summary

Cushing’s disease represents a rare but serious endocrine disorder triggered by a pituitary tumor that initiates excessive cortisol production. It manifests with a variety of symptoms including weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing’s syndrome is accountable for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without management, the 5-year survival rate is only about 50%, emphasizing the urgent requirement for effective therapies.

Diagnosing Cushing’s disease is particularly challenging because it is rare, shares symptoms with other disorders, and manifests in various ways. Only 40–60% of individuals possess a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is frequently delayed by an average of 7 years.

Cushing’s Disease Epidemiology Classification

The Cushing’s disease epidemiology segment delivers intelligence into the historical and current Cushing’s disease patient population and projected trends for the 7MM. It facilitates recognition of the causes of current and projected patient trends by examining numerous studies and perspectives of key opinion leaders.

The Cushing’s disease market document presents epidemiological analysis for the investigation period 2020–2034 in the 7MM categorized into:

Total Prevalent Cases of Cushing’s Disease
Total Diagnosed Prevalent Cases of Cushing’s Disease
Gender-Specific Diagnosed Prevalent Cases of Cushing’s Disease
Age-Specific Diagnosed Prevalent Cases of Cushing’s Disease

Cushing’s Disease Treatment Market

The primary management for Cushing’s disease is typically transsphenoidal surgery to remove the pituitary tumor, which frequently leads to remission. However, some individuals may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are utilized to control cortisol levels.

Various medications are available for managing Cushing’s disease, particularly in cases where surgery is ineffective or not feasible. One such drug is KORLYM, advanced by Corcept Therapeutics, approved for managing hyperglycemia in individuals with Cushing’s syndrome who also possess Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options encompass SIGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also utilized in the U.S., with some marketed in Europe by HRA Pharma.

SIGNIFOR (pasireotide), advanced by Recordati, was the first drug specifically approved for Cushing’s disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan’s PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery pathway.

Recordati is recognized as a prominent participant in this therapeutic area. Another key product from the organization is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which participates in the final step of cortisol synthesis. Its oral administration makes it more convenient for individuals compared to injectable therapies. ISTURISA is also being investigated for pediatric use in an ongoing Phase II trial (NCT03708900).

RECORLEV, originally advanced by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing’s syndrome who are not surgical candidates or did not achieve cure through surgery. Unlike ISTURISA, RECORLEV operates by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action.

To know more about Cushing’s disease treatment guidelines, visit @ Cushing’s Disease Management

Cushing’s Disease Pipeline Therapies and Key Companies

Relacorilant (CORT125134): Corcept Therapeutics
Clofutriben (SPI-62): Sparrow Pharmaceuticals
Atumelnant (CRN04894): Crinetics Pharmaceuticals
Lu AG13909: H. Lundbeck
ST-002: Stero Therapeutics

Discover more about Cushing’s disease drugs in development @ Cushing’s Disease Clinical Trials

Cushing’s Disease Market Dynamics

The Cushing’s disease market dynamics are anticipated to transform in upcoming years. Although Cushing’s disease is generally considered a rare disorder, expanding awareness and recent advances in research suggest that diagnoses may increase in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, particularly given the limited therapies specifically targeting Cushing’s disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options including SIGNIFOR and SIGNIFOR LAR.

Furthermore, potential therapies are being investigated for managing Cushing’s disease, and it is safe to predict that the treatment space will substantially impact the Cushing’s disease market during the projection period. Moreover, the anticipated introduction of investigational therapies with enhanced efficacy and a further improvement in the diagnosis rate are anticipated to drive the expansion of the Cushing’s disease market in the 7MM.

However, several factors may impede the expansion of the Cushing’s disease market. Due to non-specific guidelines and recommendations, individuals with Cushing’s disease frequently face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common disorders, which leave many undiagnosed or untreated; while existing therapies including ketoconazole and metyrapone approved in Europe based on limited retrospective data and utilized off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of investigational therapies.

Moreover, Cushing’s disease management poses a significant economic burden and disrupts individuals’ overall well-being and QOL. Furthermore, the Cushing’s disease market expansion may be offset by failures and discontinuation of investigational therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the condition may also impact the Cushing’s disease market expansion.

Cushing’s Disease Market Report Metrics

Study period: 2020 to 2034

Geographic coverage: The seven major markets, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan

Market size: In 2024, the Cushing’s disease market was valued at approximately USD 1 billion

Key companies: Major players active in the Cushing’s disease market include Xeris Pharmaceuticals, Recordati, Corcept Therapeutics, Sparrow Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and Crinetics Pharmaceuticals, among others

Key therapies: Leading and emerging therapies for Cushing’s disease include RECORLEV, ISTURISA, SIGNIFOR, SIGNIFOR LAR, KORLYM, Relacorilant, Clofutriben, Lu AG13909, ST-002, and Atumelnant, among others

Coverage of the Cushing’s Disease Market Report

Therapeutic Assessment: Cushing’s Disease current marketed and investigational therapies
Cushing’s Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing’s Disease Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry tactics
Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Cushing’s Disease Market Access and Reimbursement

Download the report to understand which factors are driving Cushing’s disease market trends @ Cushing’s Disease Market Trends

Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Cushing’s Disease Market Overview at a Glance
Disease Background and Overview
Guidelines, Recommendations, and Management for Cushing’s Disease
Epidemiology and Patient Population
Patient Journey
Marketed Drug
Emerging Drugs
Cushing’s Disease: Seven Major Market Analysis
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com

Postpartum Depression Market Analysis: Epidemiology Insights and Forecast Through 2034

DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034” document delivers comprehensive understanding of Postpartum Depression, historical and projected epidemiology alongside Postpartum Depression market dynamics in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postpartum Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postpartum Depression Market Forecast

Notable Highlights of the Postpartum Depression Market Report

The Postpartum Depression market valuation was assessed at ~USD 260 million in 2023 among the 7MM countries and is projected to expand with a significant CAGR during the investigation period (2020-2034).

In December 2025, Biogen Canada Inc. has reported that Health Canada has granted a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) to manage moderate to severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE represents a once-daily, 14-day oral treatment for women with PPD. Clinical investigations demonstrate this pioneering therapy can alleviate depressive symptoms as early as day 3, with significant symptom reduction by day 15, and effects that are maintained through day 45 compared to placebo.

Among the EU4 countries and the UK, the UK possessed the largest market valuation for Postpartum Depression, estimated at approximately USD 25 million in 2023.

By 2034, ZURZUVAE is projected to produce approximately USD 600 million in revenue from the postpartum depression therapeutics market across the 7MM.

Among the EU4 countries and the UK, the UK possessed the largest postpartum depression market valuation, approximately USD 25 million in 2023.

In 2023, Japan’s postpartum depression market valuation was approximately USD 20 million, with a moderate expansion anticipated by 2034.

In 2023, the aggregate number of diagnosed postpartum depression cases across the seven major countries was approximately 1,310,000.

In 2023, the aggregate number of diagnosed postpartum depression cases in the EU4 countries and the UK was approximately 460,000.

In 2023, the United States possessed the highest number of diagnosed postpartum depression cases among the seven major markets, totaling approximately 720,000, followed by the UK.

In 2023, Japan possessed approximately 126,000 diagnosed prevalent cases of postpartum depression.

ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) represent the only approved treatments for postpartum depression (PPD). ZULRESSO is administered as a continuous intravenous (IV) infusion, while the recommended dosage for ZURZUVAE is 50 mg taken orally for 14 days. Leading organizations advancing new PPD therapies include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, among others

Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, among others

The Postpartum Depression epidemiology based on gender analyzed that PPD predominantly affects females but a small proportion of males can also experience depression post-pregnancy

The Postpartum Depression market is anticipated to expand due to the condition’s rising prevalence and awareness during the projection period. Furthermore, introducing various multiple-stage Postpartum Depression pipeline candidates will substantially transform the Postpartum Depression market landscape.

Postpartum Depression Summary

Postpartum depression (PPD) represents a complex emotional and psychological disorder that affects women after childbirth. It typically manifests within the first few weeks to months following delivery and is characterized by feelings of extreme sadness, anxiety, and fatigue, which can substantially impact a mother’s capacity to care for herself and her baby.

Get a Free sample for the Postpartum Depression Market Report:

https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=libero&utm_medium=promotion&utm_campaign=kkpr

Postpartum Depression Epidemiology

Postpartum Depression Epidemiology Classification:

The Postpartum Depression market document presents epidemiological analysis for the investigation period 2020–2034 in the 7MM categorized into:

Total Prevalence of Postpartum Depression
Prevalent Cases of Postpartum Depression by severity
Gender-specific Prevalence of Postpartum Depression
Diagnosed Cases of Episodic and Chronic Postpartum Depression

Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Epidemiology Forecast

Postpartum Depression Drugs Adoption and Pipeline Advancement Activities

The drugs adoption segment concentrates on the uptake rate of potential drugs recently introduced in the Postpartum Depression market or anticipated to launch during the investigation period. The analysis encompasses Postpartum Depression market adoption by drugs, patient adoption by therapeutics, and revenue of each drug.

The document also encompasses the Postpartum Depression Pipeline Advancement Activities. It delivers valuable intelligence about different therapeutic candidates in various phases and the principal companies participating in advancing targeted therapeutics. It also examines recent developments including partnerships, acquisitions, mergers, licensing patent particulars, and other intelligence for investigational therapies.

Postpartum Depression Therapies and Key Companies

Zuranolone(SAGE-217): SAGE Therapeutics
BRII-296: Brii Biosciences Limited
RE104: Reunion Neuroscience
GH001: GH Research
Brexanolone: Sage Therapeutics
aripiprazole: Bristol-Myers Squibb

Discover more about therapies set to grab major Postpartum Depression market share @ Postpartum Depression Treatment Market

Postpartum Depression Market Drivers

ZULRESSO initiates working within 2–3 days of administration, drastically enhancing response rates compared to conventional therapies
Therapies like BRII-296 and LPCN-1154 are in early phases of clinical advancement and their approval in future can facilitate the PPD therapeutic market expansion tremendously

Postpartum Depression Market Obstacles

Limited therapies are available for managing and diagnosing PPD, thus providing profitable opportunities for investigational therapies
Increasing research and development to establish the pathophysiology and recent advancement in diagnosis provides a lucrative opportunity for the PPD market

Coverage of the Postpartum Depression Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, among others
Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, among others
Postpartum Depression Therapeutic Evaluation: Postpartum Depression current marketed and Postpartum Depression investigational therapies
Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market obstacles
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry tactics
Postpartum Depression Unmet Requirements, KOL’s perspectives, Analyst’s perspectives, Postpartum Depression Market Access and Reimbursement

To know more about Postpartum Depression companies working in the treatment market, visit @ Postpartum Depression Clinical Trials and Therapeutic Assessment

Postpartum Depression Market Report Introduction
Executive Summary for Postpartum Depression
SWOT analysis of Postpartum Depression
Postpartum Depression Patient Share (%) Overview at a Glance
Postpartum Depression Market Overview at a Glance
Postpartum Depression Disease Background and Overview
Postpartum Depression Epidemiology and Patient Population
Country-Specific Patient Population of Postpartum Depression
Postpartum Depression Current Treatment and Medical Practices
Postpartum Depression Unmet Needs
Postpartum Depression Emerging Therapies
Postpartum Depression Market Outlook
Country-Wise Postpartum Depression Market Analysis (2020–2034)
Postpartum Depression Market Access and Reimbursement of Therapies
Postpartum Depression Market Drivers
Postpartum Depression Market Barriers
Postpartum Depression Appendix
Postpartum Depression Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

It also provides Healthcare Consulting Services, which benefit in market analysis to accelerate business expansion and overcome challenges with a practical methodology.

Contact Us

Kanishk

kkumar@delveinsight.com

About DelveInsight

Contact Us

Notable Highlights of the Prurigo Nodularis Market Report:

Prurigo Nodularis Summary

Prurigo Nodularis Epidemiology

Prurigo Nodularis Epidemiology Classification:

Prurigo Nodularis Drugs Adoption and Pipeline Advancement Activities

Prurigo Nodularis Therapies and Key Companies

Prurigo Nodularis Market Advantages

Prurigo Nodularis Market Prospects

Coverage of the Prurigo Nodularis Market Report

Table of Contents

About DelveInsight

Contact Us

Essential Findings from the Cataract Pipeline Report

Cataract Summary

Cataract Treatment Analysis: Drug Profile

NPI 002: Nacuity Pharmaceuticals

CGT 1507: CGeneTech

Research Programme: Ocular Therapeutics – Plex Pharmaceuticals

Cataract Therapeutics Classification

By Product Type

By Stage

By Route of Administration

By Molecule Type

Coverage of the Cataract Pipeline Report

Table of Contents

About Us

Contact Us

Notable Highlights from the Psoriasis Market Research Report

Psoriasis Epidemiology Classification in the 7MM

Psoriasis Market Outlook

Psoriasis Drugs Market Landscape

Psoriasis Companies

Coverage of the Psoriasis Market Report

Table of Content

About Us

Contact Us

Contact Us

Essential Findings from the Brain Metastases Pipeline Report

Brain Metastases Summary

Brain Metastases Investigational Drugs Profile

ANG1005: Angiochem

Azeliragon: Cantex Pharmaceuticals, Inc.

AZD3759: Alpha Biopharma Ltd.

The Brain Metastases Pipeline report delivers insights into

Brain Metastases Companies

Brain metastases pipeline document delivers therapeutic evaluation of pipeline drugs by Administration Pathway. Products have been classified under various ROAs including

Brain Metastases Products have been classified under various Molecular types including

Coverage of the Brain Metastases Pipeline Report

Table of Contents

About Us

Contact Us

What Drives the Campylobacter Infections Market Growth?

Campylobacter Infections Market Research: Breakthrough Diagnostic Technologies

The Antibiotic Resistance Challenge

Campylobacter Infections Market Insight: Prevention and Vaccine Development

Campylobacter Infections Market Trends: Digital Health and AI Integration

Regional Considerations and Global Perspectives

Future Directions and Emerging Opportunities

Conclusion

About DelveInsight

Contact Us

About DelveInsight

Contact Us

Notable Highlights from the Cushing’s Disease Market Report

Cushing’s Disease Summary

Cushing’s Disease Epidemiology Classification

Cushing’s Disease Treatment Market

Cushing’s Disease Pipeline Therapies and Key Companies

Cushing’s Disease Market Dynamics

Cushing’s Disease Market Report Metrics

Coverage of the Cushing’s Disease Market Report

Table of Contents

About DelveInsight

Contact Us

Notable Highlights of the Postpartum Depression Market Report

Postpartum Depression Summary

Postpartum Depression Epidemiology

Postpartum Depression Epidemiology Classification: